McDermott Advised Innate Pharma on the Expansion of its Collaboration with Sanofi in the Field of Oncology

McDermott Will & Emery advised Innate Pharma on the expansion of its collaboration with Sanofi. Sanofi is licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET^TM (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKET^TM targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization.

The McDermott team that advised Innate Pharma comprised:

·         Emmanuelle Trombe, partner, Katya Ascher, Counsel, and Caroline Noyrez, associate, on Life Sciences aspects

·         Frédéric Pradelles, partner, on Competition aspects

·         Côme de Saint Vincent, Counsel, on tax aspects